

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CPBIO HOLDING COMPANY LIMITED

正大生物控股有限公司

(Incorporated in Bermuda with members' limited liability)

(Stock Code: 3839)

PROFIT WARNING

ESTIMATED PROFIT IN PRELIMINARY 2026 INTERIM RESULTS

This announcement is made by CPBIO Holding Company Limited (the “Company” and, together with its subsidiaries, the “Group”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap 571 of the Laws of Hong Kong).

The board of directors of the Company (the “Board”) wishes to inform shareholders of the Company (the “Shareholders”) and potential investors that, based on preliminary information, the Group is expected to record a consolidated profit attributable to Shareholders of approximately US\$9.5 million for the six months ended 30 June 2026 (“1H2026”) as compared to that of US\$17.0 million for the six months ended 30 June 2025 (“1H2025”). The decrease in profit was primarily due to a slowdown in animal farming sector in China which dragged down the performance of our chlortetracycline and animal health businesses.

The information contained in this announcement is based on materials currently available to the Company and the Company is still in the process of preparing the unaudited consolidated results for 1H2026. The Company expects to announce the 1H2026 results of the Group in mid-August 2026.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Chawalit Na Muangtoun
Director

Hong Kong, 22 July 2026

As at the date of this announcement, the Board comprises Mr. Soopakij Chearavanont (Chairman and Executive Director), Mr. Thirayut Phityaisarakul, Mr. Nopadol Chiaravanont, Mr. Chawalit Na Muangtoun (each an Executive Director), Ms. Kobboon Srichai, Mr. Yoichi Ikezoe (each a Non-executive Director), Mr. Surasak Rounroengrom, Mr. Cheng Yuk Wo, Mr. Edward Ko Ming Tung and Ms. Cheung Marn Kay (each an Independent Non-executive Director).